SUBSCRIBE
SUBSCRIBE
News   FDA

Merck KGaA MS Pill Cladribine Rejected by European Medicines Evaluation Agency

September 24, 2010 | 
1 min read

FRANKFURT, Sept 24 (Reuters) - European regulators dealt Merck KGaA (MRCG.DE) a major blow by recommending against its biggest pipeline drug, multiple sclerosis (MS) pill cladribine, adding to a string of setbacks at the company’s drugs unit.

FDA Approvals Regulatory Europe
MORE ON THIS TOPIC
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac